Miraculins Announces Changes to Board of Directors

Complete the form below to unlock access to ALL audio articles.
Miraculins Inc. announces the appointment of renowned fund manager Jim Mellon to the Miraculins' Board of Directors. This appointment fills a director vacancy created by the resignation of Noah Billick, who is stepping down from the Board due to personal reasons.
"The Board of Directors wishes to thank Noah for his dedication, service and many contributions to Miraculins," said Harry Bloomfield Q.C., interim Chair of the Miraculins Board. "On behalf of the Board, I also want to welcome Jim Mellon as our newest director. Jim has distinguished himself as a global investor and brings to the Board considerable international business experience and a wealth of insight along with a special understanding of the opportunities presented by emerging life science companies."
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Property, Plant and Equipment) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, a listed fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.
In addition, Mr Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, "Wake Up!" was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.